The use of ADA, IFX, CZP and GOL, especially in patients with moderate to severe COPD and heavy smokers, may be related to an increased risk of malignant tumors as found in a study on IFN (79). The gene discussed is IFNA1; the disease is chronic obstructive pulmonary disease.